Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome plus fruquintinib as second-line therapy for advanced gastric cancer
ChiCTR2400086295Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan liposome and fruquintinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Progression-free survival and Maximum tolerated dose. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
irinotecan liposomefruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400086295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086295.